BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
4.770
-0.120 (-2.45%)
At close: Sep 18, 2026, 4:00 PM EDT
4.834
+0.064 (1.34%)
After-hours: Sep 18, 2026, 7:30 PM EDT

BBOT Stock Forecast

BBOT's stock price has decreased by -55.79% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 12 analysts polled by S&P Global, BBOT stock has a consensus rating of "Strong Buy" and an average price target of $24.73. The average 1-year stock price forecast is 418.45% higher than the current stock price, while the lowest is $15 (+214.47%) and the highest is $50 (+948.22%).

Price Target: $24.73 (+418.45%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$15$24.73$22$50
Change+214.47%+418.45%+361.22%+948.22%

Analyst Ratings

The average analyst rating for BBOT stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy667777
Buy333344
Hold000000
Sell000000
Strong Sell000000
Total9910101111

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Leerink Partners
Leerink Partners
Buy
Maintains
$27$25
BuyMaintains$27$25+424.11%Sep 18, 2026
J.P. Morgan
J.P. Morgan
Buy
Reiterates
n/a
BuyReiteratesn/an/aSep 15, 2026
Unknown Analyst
Wedbush
No rating
Wedbush
Buy
Maintains
$25
BuyMaintains$25+424.11%Sep 9, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$21
BuyMaintains$21+340.25%Sep 9, 2026
Raymond James
Raymond James
Buy
Maintains
$24$22
BuyMaintains$24$22+361.22%Sep 9, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.85
from -4.30
EPS Next Year
-2.72
from -2.85
Fiscal YearFY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
----
Operating Income
-64.77M-80.86M-145.82M-223.42M
Net Income
-64.70M-74.28M-134.04M-212.18M
EPS
---4.30-2.85
Free Cash Flow
----23.00M
No. Analysts
---9
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-1.98
Avg-2.85
Low-4.61

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-